Twist Bioscience Co. (NASDAQ:TWST) Receives $118.00 Consensus Target Price from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST) have received a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $118.00.

TWST has been the subject of a number of research analyst reports. William Blair started coverage on shares of Twist Bioscience in a research report on Tuesday, June 29th. They set an “outperform” rating for the company. Zacks Investment Research raised shares of Twist Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, September 9th. The Goldman Sachs Group started coverage on shares of Twist Bioscience in a research note on Friday, June 4th. They issued a “neutral” rating and a $110.00 target price on the stock. Finally, Robert W. Baird lowered their target price on shares of Twist Bioscience from $140.00 to $130.00 and set an “outperform” rating on the stock in a research note on Monday, August 9th.

In other Twist Bioscience news, Director Keith Crandell sold 1,412 shares of the company’s stock in a transaction dated Thursday, August 12th. The shares were sold at an average price of $106.93, for a total transaction of $150,985.16. Following the sale, the director now directly owns 486 shares of the company’s stock, valued at $51,967.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Emily M. Leproust sold 2,000 shares of the company’s stock in a transaction dated Monday, July 12th. The stock was sold at an average price of $125.85, for a total transaction of $251,700.00. Following the sale, the chief executive officer now directly owns 256,556 shares in the company, valued at $32,287,572.60. The disclosure for this sale can be found here. Insiders have sold 145,148 shares of company stock worth $16,330,194 over the last ninety days. Insiders own 7.00% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Tradition Wealth Management LLC acquired a new position in shares of Twist Bioscience during the second quarter worth approximately $27,000. Itau Unibanco Holding S.A. acquired a new position in shares of Twist Bioscience during the second quarter worth approximately $28,000. Sittner & Nelson LLC lifted its position in shares of Twist Bioscience by 266.7% during the second quarter. Sittner & Nelson LLC now owns 275 shares of the company’s stock worth $37,000 after purchasing an additional 200 shares in the last quarter. Advisory Services Network LLC acquired a new position in shares of Twist Bioscience during the second quarter worth approximately $52,000. Finally, Concord Wealth Partners lifted its position in shares of Twist Bioscience by 11,040.0% during the first quarter. Concord Wealth Partners now owns 557 shares of the company’s stock worth $69,000 after purchasing an additional 552 shares in the last quarter. Institutional investors own 96.88% of the company’s stock.

Shares of TWST traded down $0.59 during trading hours on Friday, reaching $120.33. 11,225 shares of the company traded hands, compared to its average volume of 714,322. The stock’s fifty day moving average is $112.89 and its 200 day moving average is $117.12. The stock has a market cap of $5.93 billion, a P/E ratio of -42.28 and a beta of 0.70. Twist Bioscience has a 1-year low of $62.37 and a 1-year high of $214.07.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, August 5th. The company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.07). The company had revenue of $35.02 million for the quarter, compared to analyst estimates of $32.43 million. Twist Bioscience had a negative net margin of 106.59% and a negative return on equity of 24.59%. The firm’s quarterly revenue was up 65.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.67) EPS. Sell-side analysts predict that Twist Bioscience will post -3.11 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The firm also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage.

Recommended Story: Conference Calls and Individual Investors

Analyst Recommendations for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.